NATCO Pharma Limited (NSE:NATCOPHARM)
806.00
+10.45 (1.31%)
Oct 1, 2025, 3:29 PM IST
NATCO Pharma Employees
NATCO Pharma had 4,199 employees as of March 31, 2025. The number of employees increased by 183 or 4.56% compared to the previous year.
Employees
4,199
Change (1Y)
183
Growth (1Y)
4.56%
Revenue / Employee
10.47M INR
Profits / Employee
4.04M INR
Market Cap
144.46B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 4,199 | 183 | 4.56% |
Mar 31, 2024 | 4,016 | 70 | 1.77% |
Mar 31, 2023 | 3,946 | -79 | -1.96% |
Mar 31, 2022 | 4,025 | -1,021 | -20.23% |
Mar 31, 2021 | 5,046 | 20 | 0.40% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
Sun Pharmaceutical Industries | 43,000 |
Divi's Laboratories | 10,542 |
Cipla | 30,313 |
Apollo Hospitals Enterprise | 42,497 |
Mankind Pharma | 26,978 |
Zydus Lifesciences | 27,917 |
Fortis Healthcare | 12,237 |
Alkem Laboratories | 18,785 |
NATCO Pharma News
- 7 days ago - Natco Pharma board approves evaluation of Agro business demerger - Business Upturn
- 14 days ago - Natco Pharma receives US FDA’s VAI classification for Hyderabad unit - Business Upturn
- 22 days ago - Natco Pharma moves closer to Adcock Ingram acquisition with shareholder vote set for October - Business Upturn
- 6 weeks ago - Natco Pharma launches generic Bosentan tablets for oral suspension in the US with 180-day exclusivity - Business Upturn
- 6 weeks ago - Lupin launches Bosentan Tablets for Oral Suspension in US with 180-day exclusivity - Business Upturn
- 7 weeks ago - Brokerage recommendations for August 14: Muthoot Finance, Va Tech Wabag, JSPL, VMM, BPCL, Devyani, Apollo Hospitals, HDFC Life, Infosys, Brainbees, United Spirits, Motherson, Jubilant Food, PI Industries, Natco Pharma, ONGC in focus - Business Upturn
- 7 weeks ago - Natco Pharma board declares interim dividend of Rs 2 per share for FY26 - Business Upturn
- 7 weeks ago - NATCO Pharma Q1 Results: Revenue slips marginally to Rs 1,390.6 crore, net profit falls 28.1% YoY - Business Upturn